HPTN Partners with HVTN on COVID-19 Study

May 14, 2020


MC quote

The HIV Prevention Trials Network (HPTN) and HIV Vaccine Trials Network (HVTN) have initiated their first clinical trial in response to COVID-19. The study, called HVTN 405/HPTN 1901, will describe immune responses in study participants with a history of infection with SARS-CoV-2, the virus that causes COVID-19. Approximately 400 study participants aged 18 years and older will be enrolled at clinical trial sites across North and South America. Using its infrastructure of global clinical trial sites, laboratories, and biostatistical expertise, the HVTN and HPTN hope to make significant contributions to the global COVID-19 response.